What Is NAD+? The Coenzyme at the Centre of Ageing Research

Somewhere in the last sentence you read, several billion molecules picked up two electrons, carried them a few nanometres across the inside of a mitochondrion, dropped them onto the machinery that makes your cellular fuel, and went back for more. They did it without you noticing, as they have every second of your life. The courier is a coenzyme called NAD+, and the quietly unsettling fact at the centre of modern longevity research is that you have less of it than you used to — and will have less still.

That single observation — an indispensable molecule that runs low as we age — has turned an unglamorous bit of textbook biochemistry into one of the most heavily studied targets in the biology of ageing.⁴ To understand why, it helps to start not with the hype but with the chemistry.

What does NAD+ actually do in a cell?

NAD+ wears two hats. The first is its day job as a redox coenzyme. Metabolism is, at bottom, a controlled cascade of electron transfers: glucose and fat are taken apart, and the energy released is captured as electrons handed from molecule to molecule. NAD+ is the principal shuttle. It accepts a pair of electrons to become NADH, ferries them to the mitochondrial electron-transport chain, and is regenerated as NAD+ to repeat the trip. Every pathway that burns fuel — glycolysis, the citric-acid cycle, fatty-acid oxidation — runs on this loop. When mitochondrial NAD+ supply is engineered upward in injured tissue, mitochondrial function improves measurably, which is why NAD+ transport into mitochondria has become a target in models of cerebral ischaemia and reperfusion injury.¹¹

The second hat is more interesting for the ageing field. NAD+ is not only recycled; it is also consumed as a substrate by two enzyme families that spend it to do regulatory work. The sirtuins are NAD+-dependent deacylases that tune metabolism, mitochondrial quality control and stress responses; the PARPs spend NAD+ to flag and repair damaged DNA. Because both depend on NAD+ availability, the molecule behaves less like a passive battery and more like a currency — one whose abundance tells the cell how much metabolic room it has to invest in repair and maintenance.⁴ Restoring it shifts that balance: supplying NAD+ or its precursors reactivates SIRT-modulated pathways governing microtubule dynamics, mitophagy and mitochondrial housekeeping in senescent cells.¹³

Why does NAD+ decline with age?

If NAD+ is so essential, why would a cell let it run down? The answer appears to be less a failure of supply than a rise in demand. As tissues age and accumulate damage, the enzymes that spend NAD+ work harder — and one consumer in particular, the cell-surface enzyme CD38, increases with age and inflammation and draws heavily on the shared pool.³ The salvage pathway that recycles the vitamin-B3 building blocks back into NAD+ struggles to keep pace. The result is a slow net drawdown, and it is precisely this arithmetic — rising consumption against finite salvage — that motivates the two dominant intervention strategies: slow the consumers (for instance, by inhibiting CD38, now an active medicinal-chemistry target³) or top up the supply.

The decline matters because NAD+ sits upstream of so much. In the kidney, the NAD+–SIRT3 axis is implicated in the “metabolic memory” that keeps diabetic damage progressing even after blood sugar is controlled.¹ In the heart and vasculature, NAD+ metabolism is increasingly tied to cardiovascular disease.² In the liver, restoring NAD+ via precursors eased fatty-liver changes in alcohol-fed mice.⁸ And in neural tissue, correcting an NAD+-synthesis defect rescued a senescence-like phenotype seen among inherited cofactor disorders.¹⁰ The same molecule, the same logic, in organ after organ.

NAD+ versus its precursors: which one do you actually study?

Here is where the field forks, and where honest readers should slow down. You might assume the obvious way to raise cellular NAD+ is to add NAD+. It is not. NAD+ is a large, highly charged molecule, and charged molecules of that size cross the lipid membrane of a cell poorly. So although it is the endpoint everyone wants to lift, it is an awkward thing to deliver directly — which is exactly why so much of the literature works with smaller precursors that the cell’s salvage machinery converts into NAD+ once inside.

NAD+ and its two best-studied precursors. All three aim at the same endpoint — a higher intracellular NAD+ pool — but differ in how easily they reach it. For more, see our NMN primer.

This membrane problem is not a footnote; it is the engineering frontier. Researchers are now building elaborate delivery systems — ion-coupled transfersome complexes designed to push NAD+ across skin and into cells — specifically because the bare molecule will not go where it is wanted on its own.⁹ That such contraptions are necessary tells you everything about why precursors dominate the bench literature.

What does the honest evidence say — and not say?

It would be easy to read the preceding sections as a finished story: NAD+ falls, restore it, age slower. The literature does not support that leap, and pretending otherwise does the science a disservice.

First, almost all of the encouraging mechanistic work is preclinical — cell culture, engineered tissue and animal models. The kidney, liver, cerebral-ischaemia and senescence findings cited above are exactly that.¹⁸¹¹¹³ They are genuine and reproducible signals, but a benefit in a mouse kidney or a dish of senescent cells is a hypothesis about humans, not a demonstration in them. Direct-NAD+ supplementation evidence in people is thin, and the membrane-permeability problem is one reason why.⁹

Second, and more subtly: “raising NAD+” is not the same as proven anti-ageing benefit. Lifting a biomarker is not the same as living better or longer, and the gap between the two is where a great deal of longevity marketing quietly hides. The honest framing is that NAD+ is a compelling, mechanistically central target with a deep preclinical literature and still-immature human evidence — we explore the precursor side of that gap in our NAD+/NMN/NR human-evidence editorial.

Third, NAD+ metabolism cuts both ways. The same reprogramming that helps a stressed cell can serve a malignant one, and the relationship is direction-dependent: in one melanoma model, over-expressing the NAD+-synthesis enzyme NMNAT3 suppressed tumour progression by reprogramming NAD+ metabolism — a reminder that “more NAD+” is not a context-free good and that the biology is genuinely two-edged.⁵ Anyone treating NAD+ as an unalloyed positive has stopped reading the literature too early.

How is research-grade NAD+ made and characterised?

Because NAD+ is a defined small molecule rather than a peptide, it can be produced both by enzymatic synthesis⁷ and by engineered microbial pathways now capable of high-titre output⁶ — which is precisely why identity and purity verification matter. The molecule in the vial should be unambiguously NAD+, at a stated purity, free of the synthesis by-products and degradation that a charged, light- and heat-sensitive coenzyme readily accumulates. That is what a Certificate of Analysis documents: the HPLC purity figure, the identity confirmation, and the third-party testing that separates a characterised reference material from an unknown white powder. If you have never parsed one, our guide on how to read a COA walks through what each line means.

A closing note on scope, because this compound attracts exactly the kind of self-experimentation it should not. NAD+ is a research material, not an approved medicine. Nothing above is dosing guidance or a therapeutic claim; the animal and in-vitro findings are described as what they are. Condor supplies NAD+ strictly as a research-use-only reference material — not for human or veterinary use — with a Certificate of Analysis attesting to its identity and purity, so that the molecule a laboratory studies is, verifiably, the molecule it intended to study.

References

1. Zhang Y, Wang Y, Qiao Y, Liu L, Zhao H, Jin Q, et al. Targeting the NAD(+)-SIRT3 axis to mitigate metabolic memory in diabetic kidney disease. Renal Failure. 2026;48(1):2648912. PMID: 41991506. doi:10.1080/0886022X.2026.2648912.
2. Prasanna J, Manickam R, Tipparaju SM. Role of nicotinamide adenine dinucleotide in cardiovascular disease. Current Opinion in Cardiology. 2026;41(4):369–376. PMID: 42047243. doi:10.1097/HCO.0000000000001292.
3. Zhang Z, Ansari AJ, Fayne ER, Zhang Y. Emerging chemical strategies for CD38 inhibition: restoring NAD(+) metabolism and disease control. Bioorganic & Medicinal Chemistry. 2026;138:118676. PMID: 42033923. doi:10.1016/j.bmc.2026.118676.
4. Pei Z, Liang F, Wang X, Li H. NAD+ as a central metabolic hub regulating the hallmarks of aging: mechanisms and therapeutic implications. Mechanisms of Ageing and Development. 2026;231:112174. PMID: 41812700. doi:10.1016/j.mad.2026.112174.
5. Wu Y, Yu J. Overexpression of NMNAT3 suppresses melanoma progression by reprogramming NAD+ metabolism. Translational Oncology. 2026;69:102562. PMID: 42068671. doi:10.1016/j.tranon.2025.102562.
6. Li K, Sun D, Zhang D, Liu Y, Li X. High-titer nicotinamide adenine dinucleotide production via artificially designed pseudo-de novo biosynthesis pathway. Bioresource Technology. 2026;451:134529. PMID: 41916456. doi:10.1016/j.biortech.2026.134529.
7. Boyle E, Zhang O, Cen Y. Enzymatic synthesis of NAD(). Current Protocols. 2026;6(6):e70397. PMID: 42258046. doi:10.1002/cpz1.70397.
8. Cao F, Ge X, Pi A, Huang Q, Pei L, Chen R, et al. Hepatic Hamp restoration contributes to nicotinamide mononucleotide (NMN)-alleviated hepatic steatosis in chronic alcohol-fed mice. Communications Biology. 2026. PMID: 42225972. doi:10.1038/s42003-026-10398-3.
9. Kang S, Wei S, Koo BI, Jo Y, Park J, Xue Y, et al. Ion-coupled transfersome complexes for enhanced transdermal NAD(+) repletion and mitigation of cellular senescence signatures. Materials Today Bio. 2026;38:103218. PMID: 42170234. doi:10.1016/j.mtbio.2026.103218.
10. Di Meo I, Ferreira CR, Opladen T, Schwarz G, Tiranti V, van Karnebeek C, et al. Clinical and biochemical footprints of inherited cofactor disorders. Molecular Genetics and Metabolism. 2026;148(3):110163. PMID: 42176403. doi:10.1016/j.ymgme.2026.110163.
11. Wang X, Li Y, Tan J, Sun X, Zhou Q, Xu R, et al. Mitochondrial NAD(+) transport alleviates cerebral ischemia/reperfusion injury via enhancement of mitochondrial function. Antioxidants & Redox Signaling. 2026. PMID: 42209413. doi:10.1177/15230864261455714.
12. Venkateshvaran A, Pundlik SS, Suresh Y, Hegde A, Venkatesh B, Dowari S, et al. Dose-dependent effects of dihydronicotinamide riboside on human engineered skeletal muscle development. ACS Biomaterials Science & Engineering. 2026. PMID: 42206993. doi:10.1021/acsbiomaterials.5c02051.
13. Cui J, Ren S, Wang B, Zhang N, Zhu S, Zhang Y, et al. NMN/NAD(+) enhances SIRT2-modulated microtubule dynamics to improve mitochondrial and mitophagy functions in senescent cells. Autophagy. 2026:1–19. PMID: 42178923. doi:10.1080/15548627.2026.2677181.